AZRX News and Press, AzurRx BioPharma Inc. From 08/12/20

EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35%  on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...

Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) jumps  41%  after hours in reaction to positive preliminary data from a 24-subject  Phase 2 clinical trial evaluating lead candidate MS1819, combined with pancreatic enzyme replacement therapy (PERT), for the treatme...

Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achieved Clinically meaningful improvement (>80%) in coefficient of fat absorption (CFA) for all patients across all dose levels of MS1819 Topline data from full datase...

Gainers:  Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...

Eastman Kodak (NYSE: KODK )   -39%  after drug loan pause . More news on: Eastman Kodak Company, Neovasc Inc., Kazia Therapeutics Limited, Stocks on the move, , Read more ...

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

Gainers: Eastman Kodak (NYSE: KODK ) +210% . More news on: Eastman Kodak Company, Mercurity Fintech Holding Inc., Francesca's Holdings Corporation, Stocks on the move, , Read more ...

Three OPTION 2 clinical trial sites activated in the U.S. Topline data expected in Q1 2021 NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-syst...

On July 16, 2020, AzurRx BioPharma ( AZRX +1.3% ) entered into a convertible preferred stock and warrant securities purchase agreement for private placement of the same in exchange for certain O/S promissory notes. More news on: AzurRx BioPharma, Inc., Stocks on the move, Healthcare ...

Private placement resulting in gross cash proceeds of $15.2 million to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis Exchange of $6.9 million principal amount of outstanding promissory notes into private placement strengthens balance sheet NEW YORK, Ju...